Welcome to the Department of Radiation Oncology

Message from James M. Metz, MD — Chairman

Penn Radiation Oncology is dedicated to a three-part mission of excellence in patient care, basic and translational research, and the education of residents and students. We are committed to delivering excellence in every area and as such we steadfastly believe that "Excellence is Standard."

Penn Radiation Oncology is one of the most comprehensive radiation oncology programs in the world. The outstanding faculty and staff, combined with Penn’s extensive collection of advanced technology, gives patients access to nearly every treatment option available for their cancer. The broad range of radiation treatments available include Proton Therapy, intensity-modulated radiation therapy (IMRT), high-dose rate (HDR) and low-dose rate brachytherapy, partial breast irradiation, stereotactic radiosurgery (SRS), and Gamma Knife radiation. With the Abramson Cancer Center of the University of Pennsylvania, Penn Radiation Oncology provides patient care at the Ruth and Raymond Perelman Center for Advanced Medicine (PCAM), six major hospitals, and nine community-based sites.

Read more of the Message from the Chair »

News

  • Expanding the Reach of Precision Care Monday, January 12, 2026

    When the $224 million Roberts Proton Therapy Center at Penn Presbyterian Medical Center opens in late 2027, it will become Penn Medicine’s fourth proton therapy center, bolstering the organization’s system-wide approach to comprehensive cancer care and supporting upgrades at the flagship location in the Perelman Center for Advanced Medicine. “We aim to bring a world-class center of excellence with a goal of continuing the longstanding research efforts of Penn Medicine Radiation Oncology,” said the department’s Chief Operating Officer Fabian Marechal, MS.

    DDC Journal (Story begins on page 132)

  • New Research for Stage III Lung Cancer Monday, October 27, 2025

    The phase III PACIFIC-2 trial showed no significant progression-free survival benefit with adding the immunotherapy drug durvalumab to concurrent platinum-based chemoradiotherapy in patients with stage III non–small cell lung cancer that couldn’t be surgically removed. The results were published in the Journal of Clinical Oncology by Jeffrey D. Bradley, MD, a professor of Radiation Oncology, and colleagues.

    ASCO Post

  • Lower-Dose Radiation Therapy Effective in Aggressive Lymphomas Friday, October 17, 2025

    New research shows that a reduced dose of radiation therapy works just as well to keep the cancer from returning for patients with aggressive lymphomas. John P. Plastaras, MD, PhD, a professor of Radiation Oncology, noted that the findings will help physicians evaluate treatment options during tumor board discussions because “now we finally have data to inform those conversations.”

    Medscape

More News

Upcoming Events

    More Events



    Penn Medicine Radiation Oncology Instagram